All time high quarter for sales revenues, ending at MNOK 151.1, 11.4% above fourth quarter last year (MNOK 135.6). Full year sales ended at MNOK 562.6, 6.9% above last year (MNOK 526.4).
Currency neutral sales of own products was up 9.7% for the quarter and 3.9% for the full year.
Recurring sales remained high at 71.5% (71.3%) for the quarter and 73.7% (69.3%) for the year.
AMERICAS delivered a strong quarter with 29.7% currency neutral growth. EMEA showed strong performance with currency neutral growth of 10.9%. APAC was down 24.4% for the quarter.
Operating profit (EBIT) for the quarter ended at MNOK 25.8 giving a 17.1% EBIT margin (MNOK 22.3, a 16.4% margin). For the full year, EBIT was at MNOK 131,1 (MNOK 131.4) giving a 23.3% EBIT margin (25.0%).
Third-party distributor sales in Scandinavia increased 10.4% for the quarter and 13.1% for the year.
In December, Medistim launched its new MiraQ INTUI software platform for Cardiac surgery.
For vascular surgery, Medistim launched a multicenter study of TTFM and HFUS imaging as completion control in peripheral bypass.
Solid cash position at quarter end with MNOK 179.2 and no interest-bearing debt. The Board of Directors suggests a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.8 (MNOK 82.4).